Press Release

First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)

As announced, initial proof-of-concept (POC) results from distinct ongoing investigator-initiated trial (IIT) in Abu Dhabi show crofelemer reduced total parenteral support in a pediatric MVID patient with intestinal failure by up to 27%; per the IIT protocol, patient was taken off crofelemer after 12 weeks of treatment for a period of 30 days, but was restarted on daily crofelemer treatment after just 8 days, as patient's symptoms were worsening

Additional POC IIT results expected throughout 2025 for MVID; results from company's MVID Phase 2 study expected with completion of treatment in H2 2026

Ground-breaking results in single-digit number of MVID patients could potentially lead to expedited approval in the EU through PRIME and to Breakthrough Therapy designation in the US

Read More
Why Are DEA’s Prevoznik and Strait Lecturing the World on Drug Policy While Undermining U.S. Marijuana Law?
Press Release

Why Are DEA’s Prevoznik and Strait Lecturing the World on Drug Policy While Undermining U.S. Marijuana Law?

The appearance of Thomas Prevoznik and Matthew Strait as thought leaders in global drug policy is more than just tone-deaf-it's dangerous. It validates a failed regulatory approach that punishes innovation, undermines public health, and sidelines scientific progress for political convenience

Read More